PubRank

Alessandro Gentilucci

Author PubWeight™ 15.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007 1.61
2 Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010 1.04
3 Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest 2010 0.92
4 Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007 0.90
5 The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol 2011 0.88
6 Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. J Urol 2009 0.88
7 Supernumerary kidney laparoscopically treated. Can Urol Assoc J 2013 0.85
8 Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 2009 0.84
9 Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int 2009 0.83
10 Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol 2012 0.82
11 Update on screening in prostate cancer based on recent clinical trials. Rev Recent Clin Trials 2011 0.81
12 Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve-sparing radical prostatectomy. J Sex Med 2012 0.80
13 Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR). Urol Oncol 2011 0.80
14 Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery. Urol Oncol 2011 0.80
15 Bladder carcinoma: MDCT cystography and virtual cystoscopy. Abdom Imaging 2009 0.79
16 A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore) 2016 0.75
17 Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci. Urol Oncol 2009 0.75
18 Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report. Eur Urol 2007 0.75
19 Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience. Int J Urol 2014 0.75
20 Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy. Eur Urol 2007 0.75
21 [Prostate cancer unit for an optimal management of prostate cancer unit]. Urologia 2012 0.75
22 Use of 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy (RRP): a potential diagnostic tool for optimal management of erectile dysfunction after RRP. J Sex Med 2009 0.75
23 Comparative effect of finasteride and dutasteride on chromogranin A levels. Anticancer Res 2010 0.75